Quotient Therapeutics, located in Cambridge, secured an initial $50 million funding. Leading the round was Flagship Pioneering. The funds will be used by the business to progress platform development.
Under the leadership of CEO Geoffrey von Maltzahn, Ph.D., Quotient Therapeutics is an organisation dedicated to methodically investigating the genetic diversity and development of the trillions of cells which make up the human body.
With the help of its Somatic Genomics platform, researchers can uncover connections between genes and illness in an array of therapeutic domains, leading to the development of novel drugs with the potential to treat, prevent, or even reverse disease.
This platform, which was created by Flagship scientists in collaboration with geneticists at the University of Texas Southwestern and the Wellcome Sanger Institute, allows researchers to study natural selection at the cellular level through four processes: computation, isolation, single-cell genotyping, and phenotyping of cells from clinical tissue samples.
Consequently, genes, proteins, and pathways that are naturally selected are recognised as potential targets for the development of transformative treatments meant to treat, avoid, or reverse disease.
Read also – Floreon Secures £2M Series A in Funding
First-in-class medications in a wide range of therapeutic domains and modalities, such as immunological illness, cardiometabolic disease, infectious disease, oncology, neurodegenerative disease, uncommon disease, and ageing, will be feasible thanks to Quotient’s methodology.
Hao Zhu, MD, from University of Texas Southwestern, Professor Sir Mike Stratton, MD, PhD, Inigo Martincorena, PhD, and Peter Campbell, PhD, from the Wellcome Sanger Institute, and Jacob Rubens, Ph.D., President, and Noubar Afeyan, Chairman of the Strategic Oversight Board, are among the other co-founders.
Apart from von Maltzahn and Rubens, the other executives of Quotient are Simon Brunner, Ph.D., Co-Founder and Head of Platform; Caroline Fox, M.D., MPH, Senior Vice President, Head of Genetics and Target Discovery; and Scott Hayton, Ph.D., Acting Chief Operating Officer.
About Quotient Therapeutics
The first business to methodically examine the genetic diversity and development of the trillions of cells that make up the human body is Quotient Therapeutics.
With the use of the company’s Somatic Genomics platform, new connections between genes and disease are discovered in a wide range of therapeutic domains, opening up new avenues for the development of revolutionary drugs meant to treat, prevent, or even reverse illness.